Because of its ability to modulate expression of MMP‐9, which is dysregulated in RDEB and a known contributor to wound chronification in general, diacerein stands out as a promising drug candidate to improve wound healing in this patient group. This evidence concerns the gene MMP9 and recessive dystrophic epidermolysis bullosa.